The submission deadline for expressions of interest is 22 November 2024 (Friday).

• This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to the following assessments:
  • Economic assessment: Economic evaluation (EE), Budget Impact Analysis (BIA) and Household Financial Impact (HFI) Analysis
  • ELSHI assessment: Scoping review of ELSHI evidence (and systematic review and primary data collection, if deemed necessary)

The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Updated Batch 3 Call [FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments]

The following are the health technology topics for economic and ELSHI assessments to be funded under this Call for Capsule Proposals:

HTA Topics for Economic Assessment

• For Cost-Effectiveness/Utility Analysis (CEA/CUA)
  • Ranibizumab, Aflibercept and Dexamethasone as first-line treatment for Diabetic Macular Edema (DME)
  • Ranibizumab compared to Dexamethasone as first-line treatment for Macular Edema secondary to Retinal Vein Occlusion (ME-RVO)
  • Nilotinib compared with Imatinib for adult patients with Philadelphia-positive, chronic myeloid leukemia in chronic phase
  • Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 1 Diabetes Mellitus (T1DM) patients on basal insulins (i.e., Neutral Protamine Hagedorn (NPH) or long-acting insulins (LAIs))
  • Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 2 Diabetes Mellitus (T2DM) patients on non-insulin medications or basal insulins with or without other medications
  • Brentuximab Vedotin versus placebo or standard of care among adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least 2 prior therapies when ASCT or multi-agent chemotherapy are not suitable
  • Ivabradine in addition to standard of care (SOC) (i.e., beta-blockers) in comparison to SOC alone for adult patients aged 19 years old and above with Chronic Heart Failure and with Chronic Stable Angina, or with resting heart rate (HR) >70 beats per minute (bpm) who are in sinus rhythm, despite being on optimized guideline-directed medical therapy (GDMT), or when GDMT is contraindicated
  • Ticagrelor 60 mg (alone or in combination with aspirin) compared with aspirin alone or clopidogrel (alone or in combination with aspirin) for adult patients with a history of myocardial infarction (MI) at least one year ago and high risk of developing a thrombotic event

• For Cost-Minimization Analysis (CMA)
  • Ranibizumab compared to Aflibercept as first-line treatment for Wet Age-related Macular Degeneration (wAMD)

• For Model-based CMA
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors compared to sulfonylureas or SGLT2 inhibitors for adult Type 2 diabetes mellitus (T2DM) patients inadequately controlled on metformin monotherapy

HTA topics for ELSHI Assessment

• Ranibizumab, Aflibercept and Dexamethasone as first-line treatment for Diabetic Macular Edema (DME)
• Ranibizumab compared to Dexamethasone as first-line treatment for Macular Edema secondary to Retinal Vein Occlusion (ME-RVO)
• Ranibizumab compared to Aflibercept as first-line treatment for Wet Age-related Macular Degeneration (wAMD) 
• Nilotinib compared with Imatinib for adult patients with Philadelphia-positive, chronic myeloid leukemia in chronic phase
• Erdosteine compared to acetylcysteine or carbocisteine among adult patients with chronic obstructive pulmonary disease (COPD) GOLD GRADE 1 and above
• Dipeptidyl peptidase-4 (DPP-4) inhibitors compared to sulfonylureas or SGLT2 inhibitors for adult Type 2 diabetes mellitus (DM) patients inadequately controlled on metformin monotherapy
• Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 1 Diabetes Mellitus (T1DM) patients on basal insulins (i.e., Neutral Protamine Hagedorn (NPH) or long-acting insulins (LAIs))
• Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 2 Diabetes Mellitus (T2DM) patients on non-insulin medications or basal insulins with or without other medications
• Brentuximab Vedotin versus placebo or standard of care among adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least 2 prior therapies when ASCT or multi-agent chemotherapy are not suitable
• Ivabradine in addition to standard of care (SOC) (i.e., beta-blockers) in comparison to SOC alone for adult patients aged 19 years old and above with Chronic Heart Failure and with Chronic Stable Angina, or with resting heart rate (HR) >70 beats per minute (bpm) who are in sinus rhythm, despite being on optimized guideline-directed medical therapy (GDMT), or when GDMT is contraindicated
• Ticagrelor 60 mg (alone or in combination with aspirin) compared with aspirin alone or clopidogrel (alone or in combination with aspirin) for adult patients with a history of myocardial infarction (MI) at least one year ago and high risk of developing a thrombotic event

For interested researchers, kindly take note of the following important dates:

• Deadline of expression of interest: 22 November 2024 (Friday)
• Deadline for submission of requirements: 10 working days from the submission of the expression of interest

Submissions shall be sent to htaresearch@dost.gov.ph

Kindly see the call guide and Terms of Reference for more info:

Call Guide:

Terms of Reference: